We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Make the most of 2022 Lead your own way in business and beyond with our unrivalled journalism.
Add this topic to your myFT Digest for news straight to your inbox
Advisers recommend use of a third shot but want vulnerable people to have priority
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them even for viral infections, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Research underscores the dangers of bacteria developing the ability to resist drugs
Departure of Hal Barron comes as pharma group faces pressure to revive drug pipeline
The poor are continuing to bear the brunt of Covid-19
Philanthropist calls on governments to contribute billions to tackle future pathogens and increase vaccine supplies
Early findings suggest level of antibodies needed to protect against variant ‘too high’ for jab to induce
UK pharma company may still prefer to list its consumer health unit but the bar for success is now higher
Investors push for higher price or spin-off after rejecting Unilever’s £50bn offer
Chief executive deSouza attacks regulatory intervention over cancer test company
Pharma executive warns policymakers may be incapable of preparing the public for next pandemic
The division jointly owned by Pfizer is due to be spun off in London listing later this year
The consumer goods group would probably have to go higher to win, shouldering heavy debts
Hopes early warning system will give policymakers and vaccine producers more time to address health risks
Private equity companies are jointly considering an approach for UK chemist, say insiders
Top UK medical charity to focus on next generation vaccines as it warns of complacency over future variants
Swiss drugmaker to license antiviral therapeutic after success in early-stage tests
Third shot’s efficacy against symptomatic Omicron infection falls but holds up against severe cases
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs
Older inactivated virus technology in domestic shots less effective against infection than foreign rivals
Drugmakers set to take on GSK as they aim to replicate Covid jab success
Findings could help health authorities decide whether switch to variant-targeted jabs is necessary
Researchers say more than 100m suffer ill effects for at least 12 weeks
There is a good chance the global impact of coronavirus will ease
International Edition
